Repros Therapeutics (RPRX +3.3%) moves higher after providing a status update for the one year...

|About: Repros Therapeutics Inc. (RPRX)|By:, SA News Editor

Repros Therapeutics (RPRX +3.3%) moves higher after providing a status update for the one year open label extension of its Phase II clinical study of Androxal, an oral therapy designed to treat low testosterone in men.